Sino Financial Statements From 2010 to 2024
| SBMFF Stock | USD 0.45 0.03 7.14% |
Check Sino Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sino Biopharmaceutica's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sino financial statements analysis is a perfect complement when working with Sino Biopharmaceutica Valuation or Volatility modules.
Sino |
Sino Biopharmaceutical Limited Company Return On Equity Analysis
Sino Biopharmaceutica's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sino Biopharmaceutica Return On Equity | 0.29 |
Most of Sino Biopharmaceutica's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sino Biopharmaceutical Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Sino Biopharmaceutical Limited has a Return On Equity of 0.2908. This is 101.21% lower than that of the Healthcare sector and 100.8% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 193.81% lower than that of the firm.
Sino Biopharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sino Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Sino Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sino Biopharmaceutica competition to find correlations between indicators driving Sino Biopharmaceutica's intrinsic value. More Info.Sino Biopharmaceutical Limited is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.16 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sino Biopharmaceutical Limited is roughly 6.45 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sino Biopharmaceutica's earnings, one of the primary drivers of an investment's value.About Sino Biopharmaceutica Financial Statements
Sino Biopharmaceutica stakeholders use historical fundamental indicators, such as Sino Biopharmaceutica's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sino Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sino Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on Sino Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sino Biopharmaceutical Limited. Please read more on our technical analysis and fundamental analysis pages.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutic is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Sino Pink Sheet
Sino Biopharmaceutica financial ratios help investors to determine whether Sino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sino with respect to the benefits of owning Sino Biopharmaceutica security.